About Delos Capital Partners
Delos Capital Partners is a venture capital firm founded in 2014. It is primarily based out of Hong Kong, China. As of Jan 2026, Delos Capital Partners is an active investor, having invested in 29 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Healthcare. Most recently it participated in the $***** Series B round of TRexBio Overall, Delos Capital Partners portfolio has seen 5 IPOs and 3 acquisitions including key companies like Syndax, Clover Biopharma and Zenas BioPharma. A lot of funds co-invest with Delos Capital Partners, with names like New Enterprise Associates sharing a substantial percentage of its portfolio. Delos Capital Partners has team of 16 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Delos Capital Partners' List of Top Investments
Delos Capital Partners has a portfolio of 29 companies. Their most notable investments are in OncoMyx Therapeutics and Clover Biopharma.Their portfolio spans across United States, China, Taiwan and 2 more locations. They have invested in Life Sciences, Enterprise Applications, Healthcare, across Series B, Series A and 3 more. Here is the list of top investments by Delos Capital Partners:1. Syndax
Developer of targeted therapies for the treatment of cancer. The company is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer.
Key facts about Syndax
- Founded Year: 2005
- Location: Waltham (United States)
- Annual Revenue: $23.7M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $198M
- Employee Count: 326 as on Mar 31, 2026
- Investors: Aisling Capital, Boxer Capital and 18 Others
- Latest Funding Round: Post IPO, Jan 31, 2020, $*****
- Highlight: Public
Provider of access catheters for cardiovascular diagnosis and treatment. The catheters are used in deep navigation into the blood vessels of the brain to prevent strokes. The flagship product ZOOM Aspiration System is a family of products designed to facilitate clot removal during ischemic stroke.
Key facts about Imperative Care
- Founded Year: 2015
- Location: Campbell (United States)
- Stage: Series E
- Total Funding till date: $596M
- Employee Count: 388 as on Mar 31, 2026
- Investors: Bain Capital Life Sciences, Innovatus Capital Partners and 21 Others
- Latest Funding Round: Series E, Mar 13, 2026, $*****
- Highlight: Editors' Pick
3. TRexBio
Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Key facts about TRexBio
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Series B
- Total Funding till date: $219M
- Employee Count: 57 as on Mar 31, 2026
- Investors: Laurion Capital, Alexandria and 14 Others
- Latest Funding Round: Series B, Jan 27, 2026, $*****
- Highlight: Editors' Pick
4. Cardurion
Developer of therapeutics for heart and cardiovascular diseases. The propriety CRD-733, a PDE-9 inhibitor helps to improve cardiac function in heart failure patients and improves dysfunction in heart failure. The company is in its clinical stage of cardiovascular drug programs.
Key facts about Cardurion
- Founded Year: 2017
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $270M
- Employee Count: 76 as on Mar 31, 2026
- Investors: Fidelity Investments, Bain Capital Life Sciences and 11 Others
- Latest Funding Round: Series B, Jul 10, 2024, $*****
- Highlight: Editors' Pick
Developer of drugs to treat autoimmune, cancer, and infectious diseases. The company has developed its proprietary Trimer-Tag technology to develop novel, trimerized fusion-protein therapies. The trimerized fusion proteins have been shown to have a much better binding and therapeutic response. The company's drug pipeline include SCB-808, in a ready-for-injection prefilled syringe formulation and SCB-313 for Oncology.
Key facts about Clover Biopharma
- Founded Year: 2007
- Location: Chengdu (China)
- Stage: Public
- Total Funding till date: $400M
- Employee Count: 159 as on Mar 31, 2026
- Investors: Temasek, Delos Capital and 8 Others
- Latest Funding Round: Post IPO, Apr 02, 2024, $*****
- Highlight: Public
Delos Capital Partners' Year-on-Year Investment Trends
Delos Capital Partners has invested in 29 companies over the last 11 years, with an average of 1 new investment annually in the last 10 years. As of Jan 2026, it has made 2 investments in this year. Its most recent first time investment was in STRM.BIO and most recent follow-on round was in TRexBio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 1 | 2 |
2025 | 0 | 0 | 0 |
2024 | 3 | 1 | 4 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2019 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2017 | 2 | 0 | 2 |
Delos Capital Partners' Investments by Stage
Delos Capital Partners has made 6 investments in Series B stage with an average round size of $85.4M, 4 investments in Series A stage with an average round size of $145M, 2 investments in Series C stage with an average round size of $140M, 2 investments in Series D stage with an average round size of $32.2M and 1 investment in Seed stage with an average round size of $8M.Stage of entry | No. of Investments |
|---|---|
Series B | 6 |
Series A | 4 |
Series C | 2 |
Series D | 2 |
Seed | 1 |
Note: We have considered here, only first round of investments
Delos Capital Partners' Investments by Sector
Delos Capital Partners has a diverse portfolio, with companies operating in the Life Sciences, Healthcare and Sustainability Tech. Notably, it has invested in 21 Enterprise (B2B) companies, 21 Tech companies, 3 Tech hardware companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 11 |
Healthcare | 4 |
Sustainability Tech | 3 |
Note: We have considered here, only first round of investments
Delos Capital Partners' Investments by Geography
Delos Capital Partners has made most investments in United States (12), followed by China where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 12 |
China | 2 |
Germany | 1 |
Note: We have considered here, only first round of investments
Delos Capital Partners' recent investments
Delos Capital Partners has made 2 investments in 2026 so far - TRexBio and STRM.BIO.Here are the most recent investments by Delos Capital Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 27, 2026 | United States | Series B | 3221 | ||
Jan 07, 2026 | United States | Seed | 9244 | [+2] | |
Nov 18, 2024 | United States | Series A | 5214 | [+11] | |
Nov 07, 2024 | United States | Series B | 4685 | [+6] | |
Jul 10, 2024 | United States | Series B | 1070 | [+10] |
IPOs and Publicly Listed companies in Delos Capital Partners' Portfolio
5 of Delos Capital Partners' portfolio companies have become public. Zenas BioPharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Sep 2024 at marketcap of $676M and AP Biosciences got listed on the Taipei Stock Exchange (TT).Here are Delos Capital Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 13, 2024 | May 03, 2024 | Series C | 4718 | |
Jul 14, 2023 | - | - | 1193 | |
Nov 05, 2021 | Nov 27, 2019 | Series B | 5538 | |
Oct 26, 2017 | - | - | 7325 | |
Mar 03, 2016 | Aug 28, 2015 | Series C | 6901 |
Acquired companies in Delos Capital Partners' Portfolio
3 companies from Delos Capital Partners' portfolio have been acquired. The most recent acquisition was Truvic in Jul 2021 by Imperative Care for $*****.Here are Delos Capital Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 15, 2021 | - | - | 5785 | |
Feb 01, 2021 | - | - | 5639 | |
Oct 02, 2017 | - | - | 7190 |
Team profile of Delos Capital Partners
Delos Capital Partners has a team of 16 members including 5 Partners and 1 Principal located in China, Taiwan and 1 more location. Delos Capital Partners' team does not sit on the board of any company as of now.Here is a list of top team members in Delos Capital Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Taipei | - | - | |
Partner | Taiwan | - | - | |
Partner | Hong Kong | - | ||
Partner | Cambridge | - | - | |
Partner | Cambridge | - | ||
Principal | Jing an | - |
Co-investors of Delos Capital Partners
Over the past 11 years, 136 investors have co-invested in Delos Capital Partners's portfolio companies. This includes funds and angels.
- Invested before Delos Capital Partners: Polaris Partners, Domain Associates and 43 others have invested in rounds before Delos Capital Partners. There are 2 companies where Polaris Partners has invested before Delos Capital Partners and 1 company where Domain Associates has invested before Delos Capital Partners.
- Top Co-investors of Delos Capital Partners: 49 investors entered a company along with Delos Capital Partners. These include investors like New Enterprise Associates (3 companies).
- Invested after Delos Capital Partners: A total of 42 investors have invested in Delos Capital Partners's portfolio after their investments. Top Investors include Delos Capital (6 companies), Orbimed (2 companies) and Janus Henderson Investors (1 company).
Recent News related to Delos Capital Partners
•
•
•
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Developmentintelligence360•Nov 21, 2024•TRexBio, Delos Capital Partners, Delos Capital, Avego and 7 others
•
•
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology PipelineBusiness Wire•Mar 26, 2024•Avenzo Therapeutics, New Enterprise Associates, Sofinnova Investments, Deep Track Capital and 23 others
•
•
Wynnchurch Capital Acquires FCA PackagingCalgary Herald•Jul 21, 2022•FCA, Wynnchurch Capital, Delos Capital Partners, Foss Floors and 1 other
•
•
•
China's Clover raises $230 mln, plans vaccines for COVID-19 variantsFinancial Post•Feb 22, 2021•Clover Biopharma, Temasek, Oceanpine Capital, Orbimed and 5 others
